BiliaryTractCancer near Newburgh, NY

Biography: Benjamin Izar, MD, PhD is an assistant professor of medicine at the Columbia Vagelos College of Physicians and Surgeons in the division of Hematology/Oncology and a member of the Tumor Biology and Microenvironment Program at the Herbert Irving Comprehensive Cancer Center. Dr. Izar's clinical practice focuses on melanoma and cancer immunotherapy. In his lab, Dr. Izar studies interactions between cancer cells and cells of the tumor-microenvironment, and how these define metastatic niches, response and resistance to cancer immunotherapies. His lab develops and uses cutting-edge single-cell genomics and genome-editing tools to study patient tumors and models at unprecedented resolution Dr. Izar received his MD/PhD at Justus Liebig University in Giessen, Germany, where he was graduated summa cum laude. He completed his internal medicine residency training at Massachusetts General Hospital and medical oncology training at Beth Israel Deaconess Medical Center, followed by his first faculty position at Danna-Farber Cancer Institute. He completed post-doctoral research training in cancer immunology at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard. In addition to several awards he received during his training, Dr. Izar is the recipient of multiple national awards, including a NIH/NCI K08 Award (2017) and the prestigious Burroughs Welcome Fund Career Award for Medical Scientists (2018), and he was selected as a NextGen Star of the American Association for Cancer Research (2019). In 2020, he was selected as a Louis V. Gerstner, Jr. Scholar and a Velocity Fellow by Columbia University Vagelos College of Physicians and Surgeons. Dr. Izar is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the Society for Immunotherapy of Cancer, and the Society for Melanoma Research.

Biography: Dr. Stergios Zacharoulis, MD is an Oncology Specialist who practices in New York, NY. He is 55 years old and has been practicing for 30 years. Dr. Stergios Zacharoulis, MD is affiliated with Newyork-Presbyterian/Columbia University Medical Center and Newyork-Presbyterian/Morgan Stanley Children's Hospital.

Biography: Mariam El-Ashmawy, MD PhD is a medical oncologist andtranslational scientist with specialization in the treatment of advanced skincancer and ocular melanoma. Her research investigates the complex geneticlandscape of cancer in order to develop new therapies. In the laboratory, her work has been dedicated to understanding the complex genomic landscape of cancer and developing novel targeted therapeutic strategies. Her ongoing projects include testing novel RAS pathway inhibitors in preclinical models of gastric and esophageal cancer as well as a first-in-human clinical trials for patients with NRAS mutant melanoma.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Dr. Timothy Wang is a leading expert in gastroenterology cancer research and patient care. His research specifically focuses on transgenic/ knockout mice, stem cells, lineage tracing, bone marrow-derived cells, and FACS analysis of immune/epithelial cells in the gut. His laboratory has for decades investigated the molecular mechanisms of gastrointestinal carcinogenesis, and has been continuously funded by the NIH for 29 years and by the NCI for 14 years. His lab has worked for many years on the role of inflammation in promoting gastrointestinal neoplasia, including colon cancer. His research has defined key roles for stromal cells in tumor development, including myeloid cells. Dr. Wang is the GI Division Chief at Columbia and serves as Co-leader of the Tumor Biology and Microenvironment Program of the Herbert Irving Comprehensive Cancer Center. He also serves as director of the Columbia University NCI U54 Tumor Microenvironment (TMEN) program and directs the Barretts Esophageal Translational Research Network (BETRNet) program and the Intestinal Stem Cell Consortium (ISCC) at Columbia. In addition to his leadership at Columbia, Dr. Wang has served as President of the American Gastroenterology Association (AGA). His work has been recognized with numerous awards, including the Outstanding Investigator Award from the NCI, the Irene and Arthur Fishberg Prize for medical research, the Ruth Leff Siegel Award for pancreatic cancer research, and the William Beaumont Prize in Gastroenterology from the AGA. Over his career, he has organized numerous conferences, including conferences on Gastrin, Regulatory Peptides, AACR Symposium on Gastric Cancer, Tumor Microenvironment, and Keystone Conferences.

Biography: James H. Garvin, MD, PhD, is a board-certified pediatric hematologist-oncologist who specializes in the care of children and adolescents with brain tumors. He is Principal Investigator at CUMC for the Head Start Program of radiation-sparing intensive chemotherapy for infants and young children with brain tumors. He was principal investigator for a Children's Oncolgy Group protocol for childhood ependymoma. He also offers novel therapies for recurrent brain tumors through our program's membership in Developmental Therapeutics Program of the COG. In addition, Dr. Garvin started the pediatric bone marrow transplant program, and continues as a member of the BMT group. He has particular interest in autologous transplant for brain tumors and allogeneic transplant for metabolic disorders and bone marrow failure syndromes, as well as supportive care for BMT patients. Dr. Garvin became interested in pediatric hematology/oncology through research during medical school in the laboratory of a pediatric hematologist. He is a member of numerous professional societies in the field.

Biography: Dr. Sathe completed her Residency in Internal Medicine at NYP/Weill Cornell and is a graduate of Rutgers-New Jersey Medical School. She also holds a JD from Columbia Law School. Her research focuses on improving cancer care delivery and reducing disparities in treatment and outcomes.